A review finds that GLP-1 receptor agonists and DPP-4 inhibitors not only improve blood sugar but also enhance wound healing, reduce inflammation, and improve antibiotic effectiveness in diabetic foot ulcers through AMPK, mTOR, and VEGF pathways.
15% of diabetics develop foot ulcersGLP-1 receptor agonists and DPP-4 inhibitors may improve outcomes through AMPK, mTOR, and VEGF pathways while enhancing antibiotic effectiveness
What the researchers found
The review identifies multiple mechanisms by which GLP-1 receptor agonists and DPP-4 inhibitors improve diabetic foot ulcer outcomes:
- Reduce AGE formation and AGE-RAGE-NF-κB inflammatory signaling caused by chronic hyperglycemia
- Promote macrophage polarization from pro-inflammatory M1 to reparative M2 phenotype
- Enhance angiogenesis, inflammation resolution, and tissue regeneration through AMPK, mTOR, and VEGF signaling
- Glycemic stability (via CGM and antihyperglycemic adherence) improves immune cell function and reduces bacterial virulence, enhancing antibiotic effectiveness
- An integrated approach addressing both metabolic and microbial factors is advocated to restore wound homeostasis and reduce amputation risk
Why it matters
Diabetic foot ulcers remain a leading cause of non-traumatic amputations worldwide. While antibiotics and wound care are standard treatments, this review highlights that the type of diabetes drug used matters — GLP-1 drugs may actively promote healing beyond just controlling blood sugar. This could change how clinicians approach diabetic wound management, prioritizing drugs with wound-healing benefits.
How the study worked
This is a narrative review consolidating molecular evidence on the combined effects of glycemic control (using metformin, GLP-1 RAs, and DPP-4 inhibitors) and antibiotic therapies in diabetic foot ulcers. The review examines molecular pathways, immune mechanisms, and clinical evidence for integrated metabolic-antimicrobial management.
What this study cannot tell us
As a narrative review, this does not present original data or conduct a systematic search. Much of the evidence for GLP-1 effects on wound healing comes from preclinical studies, with limited clinical trial data specifically in diabetic foot ulcers. The molecular pathways described are largely based on in vitro and animal studies. Controlled clinical trials specifically testing GLP-1 drugs for diabetic foot ulcer outcomes are needed.
How to read the evidence
This is a narrative review synthesizing molecular and clinical evidence. While it provides a compelling mechanistic framework, the evidence is largely preclinical, and randomized trials specifically testing these hypotheses in diabetic foot ulcers are lacking.
When this study was published
Published in 2025, this is a very current review reflecting the latest molecular understanding of how diabetes drugs affect wound healing.
The bigger picture
GLP-1 drugs are increasingly recognized for benefits beyond blood sugar and weight — including cardiovascular, kidney, and now potentially wound healing effects. This review adds to the evidence that choosing the right diabetes medication matters for complication management, not just glycemic control. As antimicrobial resistance grows, the synergy between metabolic control and antibiotic effectiveness becomes increasingly important.
Questions still open
- Would a randomized trial comparing GLP-1 drugs versus other diabetes medications show better diabetic foot ulcer outcomes?
- Can topical application of GLP-1 or its analogues directly to wound sites accelerate healing?
- How does continuous glucose monitoring-guided therapy specifically affect wound healing compared to standard monitoring?
Common questions
Can diabetes drugs help heal foot ulcers?
Why does blood sugar control affect antibiotic effectiveness?
Read the original research
From Control to Cure: Insights into the Synergy of Glycemic and Antibiotic Management in Modulating the Severity and Outcomes of Diabetic Foot Ulcers.
International journal of molecular sciences, 26(14)
Citation
Omotosho, Idris Ajibola; Shamsuddin, Noorasyikin; Zaman Huri, Hasniza; Chong, Wei Lim; Rehman, Inayat Ur. (2025). From Control to Cure: Insights into the Synergy of Glycemic and Antibiotic Management in Modulating the Severity and Outcomes of Diabetic Foot Ulcers.. International journal of molecular sciences, 26(14). https://doi.org/10.3390/ijms26146909